Search clinical trials for: Extrahepatic

Total 177 results

MacroGenics

Completed

RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma

Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers

Unresectable Extrahepatic Bile Duct Carcinoma | Unresectable Gallbladder Carcinoma | Stage IIIA Gallbladder Cancer AJCC v7 | Stage IIIB Gallbladder Cancer AJCC v7 | Stage IVA Gallbladder Cancer AJCC v7 | Stage IVB Gallbladder Cancer AJCC v7 | Stage III Intrahepatic Cholangiocarcinoma AJCC v7 | Stage... and other conditions

United States
H. Lee Moffitt Cancer Center and Research Institute
Bayer

Completed

Single Agent Regorafenib in Refractory Advanced Biliary Cancers

Cancer of the Bile Duct

United States
First People's Hospital of Hangzhou

Completed

Clinical Effect and Safety of PDT and RFA for Unresectable EHCC

Cholangiocarcinoma

China
Theresienkrankenhaus und St. Hedwig-Klinik GmbH
Universitätsmedizin Mannheim

Completed

Primary Versus Secondary Metal Stent Implantation in PTBD

Bile Duct Obstruction | Extrahepatic Cholestasis

Germany
H. Lee Moffitt Cancer Center and Research Institute
Bayer

Completed

Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma

Cholangiocarcinoma | Gastrointestinal Tumor | Gall Bladder Carcinoma | Biliary Carcinoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers

Depression | Small Cell Lung Cancer | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Malignant Mesothelioma | Non-small Cell Lung Cancer | Liver Cancer | Anxiety Disorder | Extrahepatic Bile Duct Cancer

United States
Woo Hyun Paik

Terminated

The Effect of Aspirin on Patency of Metal Stent in Malignant Distal Bile Duct Obstruction

Biliary Stasis, Extrahepatic

Korea, Republic of
Azienda Ospedaliera Universitaria Integrata Verona

Unknown

Non-invasive Methods and Surgical Risk Stratification in Cirrhotics Undergoing Elective Extrahepatic Surgery

Surgery--Complications | Advanced Chronic Liver Disease

France, Denmark, Switzerland, United States, Austria, Canada, Germany, Hong Kong, Italy, Korea, Republic of, Spain, United Kingdom
Sun Yat-sen University

Active, not recruiting

Adjuvant Immunotherapy Combined With Chemoradiation for Patients With High-risk reseCtable Extrahepatic chOlangiocaRcinoma and gallblaDder Cancer (ACCORD)

Biliary Tract Cancer | Gallbladder Cancer | Extrahepatic Cholangiocarcinoma

China
National Cancer Institute (NCI)

Completed

A Population-Based Case-Control Study of Biliary Tract Cancers in Shanghai, China

Biliary Tract Cancer

China
Abramson Cancer Center of the University of Pennsylvania
National Cancer Institute (NCI)

Completed

Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions

Cancer

United States
University of Chicago
National Cancer Institute (NCI)

Completed

Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies

Mucinous Adenocarcinoma of the Rectum | Signet Ring Adenocarcinoma of the Rectum | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Stage III Pancreatic Cancer | Stage IV Pancreatic... and other conditions

United States
Clinical Hospital Colentina
Catholic University, Italy

Completed

EUS Evaluation of CBD Diameter in Malignant Obstructive Jaundice (ECCO)

Pancreatic Cancer | Jaundice, Obstructive | Cholangiocarcinoma of the Extrahepatic Bile Duct | Ampulla of Vater Cancer

Romania
NCIC Clinical Trials Group

Completed

Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen

Cancer

Canada
Halozyme Therapeutics

Terminated

Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

Cholangiocarcinoma Non-resectable | Cholangiocarcinoma, Extrahepatic | Cholangiocarcinoma, Intrahepatic | Gallbladder Adenocarcinoma

United States, Korea, Republic of, Thailand
Gangnam Severance Hospital
Korea Institute of Science and Technology

Completed

Development of a New Immunochemistry Method Using Antibodies of Proteins Related Bile Duct Cancer

Bile Duct Obstruction, Extrahepatic

Korea, Republic of
PCI Biotech AS

Completed

A Phase I/II Safety and Efficacy Study of PCI of Gemcitabine and Chemotherapy in Patients With Cholangiocarcinomas

Cholangiocarcinoma

Germany, France, Norway, United Kingdom
National Cancer Institute (NCI)

Terminated

Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery

Malignant Neoplasm | Recurrent Extrahepatic Bile Duct Cancer | Recurrent Gallbladder Cancer | Unresectable Extrahepatic Bile Duct Cancer | Unresectable Gallbladder Cancer | Adenocarcinoma of the Gallbladder | Adenocarcinoma of the Extrahepatic Bile Duct

United States
Innovative Digestive Health Education and Research...
NinePoint Medical

Unknown

Volumetric Laser Endomicroscopy's (VLE) Diagnostic Accuracy Validation Study: Impact on Clinical Management Study (VLE-IOV)

Cholangiocarcinoma | Bile Duct Cancer | Primary Sclerosing Cholangitis | Bile Duct Diseases | Pancreatic Ductal Adenocarcinoma | Pancreas Cancer | Bile Duct Neoplasms | Biliary Stricture | Bile Duct Obstruction | Bile Duct Obstruction, Extrahepatic | Pancreatic Duct Stricture | Bile Duct Lesions | Bile Duct Neoplasms... and other conditions

United States
Samsung Medical Center

Unknown

Study of GEMOX(Gemcitabine/Oxaliplatin) Versus XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma

Biliary Tract (Intrahepatic, Extrahepatic Cholangiocarcinoma, Gall Bladder) Cancer

Korea, Republic of
Swiss Group for Clinical Cancer Research

Completed

E-MOSAIC Electronic Tool to Monitor Symptoms

Cancer

Switzerland
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Recurrent Extrahepatic Bile Duct Cancer | Unresectable Extrahepatic Bile Duct Cancer | Cholangiocarcinoma of the Extrahepatic Bile Duct | Cholangiocarcinoma of the Gallbladder and other conditions

United States
University Hospital, Geneva
Gastaldi Giacomo; Clément Sophie

Completed

Extrahepatic Insulin Resistance in Chronic Hepatitis C

Insulin Resistance

Switzerland
University of Cape Town

Unknown

Self-expandable Metal Stents Versus Multiple Plastic Stents for Palliation of Biliary Obstruction

Biliary Stricture | Cancer of the Pancreas | Bile Duct Obstruction, Extrahepatic | Cancer of the Bile Duct

South Africa
Shanghai Jiao Tong University School of Medicine
RenJi Hospital; Huashan Hospital; Ruijin Hospital; Eastern Hepatobiliary Surgery...

Unknown

Chemothetapy FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Gallbladder Cancer | Cholangiocarcinoma of the Extrahepatic Bile Duct

China
Shanghai Jiao Tong University School of Medicine
RenJi Hospital; Huashan Hospital; Ruijin Hospital; Eastern Hepatobiliary Surgery... and other collaborators

Unknown

Molecularly Target Therapy With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Gallbladder Cancer | Cholangiocarcinoma of the Extrahepatic Bile Duct

China
Montefiore Medical Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer

Gastric Cancer | Pancreatic Cancer | Small Intestine Cancer | Liver Cancer | Extrahepatic Bile Duct Cancer | Gastrointestinal Carcinoid Tumor

United States
Montefiore Medical Center
National Cancer Institute (NCI)

Completed

Irinotecan and Capecitabine in Treating Patients With Solid Tumors

Cancer

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Completed

Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer

Nausea | Vomiting | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Extrahepatic Bile Duct Cancer | Stage II Pancreatic Cancer

United States
New Mexico Cancer Care Alliance

Terminated

Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers (Gem-ox)

Hepatocellular Carcinoma | Bile Duct Cancer | Gallbladder Cancer | Cholangiocellular Carcinoma | Extrahepatic Bile Duct Cancer | Cholangiocarcinoma of the Extrahepatic Bile Duct | Periampullary Adenocarcinoma

United States
Theresienkrankenhaus und St. Hedwig-Klinik GmbH

Completed

Ultrasound-guided Percutaneous Biliary Drainage With Primary Metal Implantation by Endoscopic Luminal Guidance

Bile Duct Obstruction, Extrahepatic

Germany
Shanghai Jiao Tong University School of Medicine
RenJi Hospital; Huashan Hospital; Ruijin Hospital; Eastern Hepatobiliary Surgery... and other collaborators

Unknown

Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Gallbladder Cancer | Cholangiocarcinoma of the Extrahepatic Bile Duct

China
University of British Columbia

Completed

Winged Perimeter Versus Traditional Plastic Biliary Stent for Malignant Bile Duct Obstruction

Malignant Tumor of Extrahepatic Bile Duct

Canada
National Cancer Institute (NCI)

Completed

Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Recurrent Extrahepatic Bile Duct Cancer | Recurrent Gallbladder Cancer | Unresectable Extrahepatic Bile Duct Cancer | Unresectable Gallbladder Cancer | Adult Primary Hepatocellular...

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct

Gallbladder Cancer | Extrahepatic Bile Duct Cancer

United States
Memorial Sloan Kettering Cancer Center

Withdrawn

Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish Individuals Who Have Cancer

Melanoma | Gastric Cancer | Non-Hodgkin's Lymphoma | Lung Cancer | Gallbladder Cancer | Extrahepatic Bile Duct Cancer | Uterine Cancer | CORPUS UTERI,ENDOMETRIUM | LUNG | OVARY

United States
Asan Medical Center
Bayer

Unknown

Efficacy and Safety of Concurrent TACE and Sorafenib in Patients With HCC and Extrahepatic Metastasis (COTSOM Study) (COTSOM)

Hepatocellular Carcinoma | Metastasis

Korea, Republic of
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Terminated

Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer

Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Small Intestine Cancer | Anal Cancer | Liver Cancer | Primary Peritoneal Cavity Cancer | Gallbladder Cancer | Extrahepatic Bile Duct Cancer | Nausea and Vomiting | Carcinoma of the Appendix | Gastrointestinal Carcinoid Tumor

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma

Gallbladder Cancer | Extrahepatic Bile Duct Cancer

United States
National Cancer Institute (NCI)

Completed

Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery (S1310)

Hilar Cholangiocarcinoma | Advanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Recurrent Adult Liver Carcinoma | Recurrent Gallbladder Carcinoma | Stage IV Distal Bile Duct Cancer | Unresectable Extrahepatic Bile Duct Carcinoma | Stage II Gallbladder Cancer | Stage... and other conditions

United States
Assiut University

Completed

Role of Complete Blood Picture in Predicting the Etiology of Extrahepatic Cholestasis

Extrahepatic Cholestasis
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Completed

Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer

Pancreatic Cancer | Small Intestine Cancer | Liver Cancer | Gallbladder Cancer | Extrahepatic Bile Duct Cancer | Periampullary Adenocarcinoma

United States
National Cancer Institute (NCI)

Terminated

Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder

Gastrointestinal Cancer | Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Recurrent Extrahepatic Bile Duct Cancer | Recurrent Gallbladder Cancer | Unresectable Extrahepatic Bile Duct Cancer | Unresectable Gallbladder... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma

Unresectable Extrahepatic Bile Duct Carcinoma | Recurrent Cholangiocarcinoma | Non-Resectable Cholangiocarcinoma | Stage III Intrahepatic Cholangiocarcinoma | Stage IIIA Hilar Cholangiocarcinoma | Stage IIIB Hilar Cholangiocarcinoma | Stage IVA Hilar Cholangiocarcinoma | Stage IVA Intrahepatic Cholangiocarcinoma and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer

Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Small Intestine Cancer | Anal Cancer | Liver Cancer | Gastrointestinal Stromal Tumor | Gallbladder Cancer | Extrahepatic Bile Duct Cancer | Carcinoma of the Appendix | Gastrointestinal Carcinoid Tumor

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Quality of Life in Patients Undergoing Radiation Therapy for Primary Lung Cancer, Head and Neck Cancer, or Gastrointestinal Cancer

Head and Neck Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Small Intestine Cancer | Lung Cancer | Anal Cancer | Liver Cancer | Gallbladder Cancer | Extrahepatic Bile Duct Cancer

United States
Roswell Park Cancer Institute
Genentech, Inc.

Completed

A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts

Cholangiocarcinoma

United States
National Cancer Institute (NCI)

Terminated

Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Recurrent Extrahepatic Bile Duct Cancer | Recurrent Gallbladder Cancer | Unresectable Extrahepatic Bile Duct Cancer | Unresectable Gallbladder Cancer | Cholangiocarcinoma... and other conditions

United States
Karolinska University Hospital
Bengt Isaksson; Jansson, Anders, M.D.

Unknown

Intra Versus Extrahepatic Division of Right Hepatic Vein During Rightsided Hemihepatectomy

Reduction of Peroperative Blood Loss During Liver Resection

Sweden

Search clinical trials for: Extrahepatic

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Togo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations